Elsevier's Maturitas Publishes Position Statement on Menopause for Medical Students
Amsterdam, March 20, 2014
Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the publication of a position statement by the European Menopause and Andropause Society (EMAS) in the journal Maturitas on the topic of the essential menopause curriculum for medical students.
The menopause, or the cessation of the menstrual cycle, is the result of ovarian aging and is a natural event experienced by most women in their late 40s or early 50s. With increasing longevity the menopause can now be considered to be a midlife event. Thus managing postmenopausal health is a key issue for all health professionals, not just gynaecologists.
Discussions with patients about the menopause are becoming more complex because of women’s increasing longevity, the wide range of therapeutic options, the controversies regarding menopausal hormone therapy and the increasing use of alternative and complementary therapies. The published position statement provides guidance in bullet-point style on the essential issues that medical students need to know about the stages of reproductive aging, menopause terminology, menopause and postmenopausal health. Management strategies should be holistic and include diet and lifestyle, menopausal hormone therapy, non-estrogen based treatments for menopausal symptoms and osteoporosis and alternative and complementary therapies. The treatment of choice for premature menopause is menopausal hormone therapy until the average age of the natural menopause (i.e. late 40s early 50s).
These and other recommendations presented in EMAS’ position statement are published in the article: “EMAS Position statement: Menopause for medical students” by Janet Brockie, Irene Lambrinoudaki, Iuliana Ceausu, Herman Depypere, C. Tamer Erel, Faustino R. Pérez-López, Karin Schenck-Gustafsson, Yvonne van der Schouw, Tommaso Simoncini, Florence Tremollieres and Margaret Rees.
The article appears in Maturitas (doi:10.1016/j.maturitas.2014.02.007) and is available on ScienceDirect.
Copies of this paper are available to credentialed journalists upon request; please contact Elsevier's Newsroom at firstname.lastname@example.org or +31 20 4853564
About European Menopause and Andropause Society (EMAS)
EMAS promotes the study of midlife health through its journal, congresses, schools and website and encourages the exchange of research and professional experience between members.
Using a range of activities and through its affiliates, EMAS aims to guarantee and provide the same standard of education and information throughout Europe on midlife health in both genders. Recognizing the issues arising from increased longevity the society also provides articles, patient information, web resources, and referrals for healthcare providers in the field and keeps its members up-to-date.
For more information go to: http://www.emas-online.org/
Maturitas is an international multidisciplinary peer reviewed scientific journal of midlife health and beyond, publishing original research, reviews, consensus statements and guidelines. The scope encompasses all aspects of post reproductive health in both genders ranging from basic science to health and social care. http://www.maturitas.org/
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
+31 20 485 3323